MedTrace Logo

An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

NCT00893113 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2018-03-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effect of Alfuzosin in treating Erectile Dysfunction in men with mild lower urinary tract symptoms based upon a change from baseline in erectile function (EF) domain of International Index of Erectile Function (IIEF).

Conditions

Interventions

DRUG

Placebo

Alfuzosin-matched One tablet once daily

DRUG

Alfuzosin

10 mg once daily

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Chesapeake Urology Research Associates

    lead OTHER

Principal Investigators

  • Ronald F Tutrone, MD · Chesapeake Urology Research Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
69 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00893113 on ClinicalTrials.gov